Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-carnitine for nutritional status and dialysis adequacy in hemodialysis patients
IRCT20191104045328N27Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of levocarnitine in end-stage kidney disease (ESKD), sponsored by Arak University of Medical Sciences. Primary endpoints: Nutritional status and Dialysis adequacy. Started Sep 2024; status: completed.
02
Drugs
levocarnitine
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20191104045328N27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191104045328N27.